Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, June 14, 2022
[ Tue, Jun 14th 2022
] - WOPRAI
[ Tue, Jun 14th 2022
] - WOPRAI
[ Tue, Jun 14th 2022
] - WOPRAI
[ Tue, Jun 14th 2022
] - WOPRAI
[ Tue, Jun 14th 2022
] - WOPRAI
Mon, June 13, 2022
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
[ Mon, Jun 13th 2022
] - WOPRAI
Andreas Argyrides Initiated (BMRN) at Hold and Held Target at $70 on, Jun 13th, 2022
Andreas Argyrides of Wedbush, Initiated "BioMarin Pharmaceutical Inc." (BMRN) at Hold and Held Target at $70 on, Jun 13th, 2022.
Andreas has made no other calls on BMRN in the last 4 months.
There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 0 agree with Andreas's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Andreas
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $106 on, Monday, June 6th, 2022
- Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $113 on, Monday, April 25th, 2022
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $125 on, Thursday, February 24th, 2022
